重组人血管内皮抑素联合榄香烯治疗晚期肝癌16例临床观察  

Effect of endostar combined elemene on patients with advanced liver cancer

作　　者：朱蔚[1] 史恒军[1] 丁井永[1] 任秦有[1] 梁军[1] 郑瑾[1] 杨建刚[1] 王珂[1] 张辉[1] 张晓娟[1] 李惠[1] 

机构地区：[1]第四军医大学唐都医院中西医结合肿瘤专科,陕西西安710038

出　　处：《现代肿瘤医学》2014年第8期1875-1879,共5页Journal of Modern Oncology

摘　　要：目的:观察重组人血管内皮抑素联合榄香烯治疗晚期肝癌的临床疗效。方法:选取唐都医院中西医结合肿瘤专科2009年3月至2011年3月期间住院的晚期肝癌患者36例,分为研究组16例和对照组20例。研究组采用重组人血管内皮抑素联合榄香烯,对照组采用华蟾素治疗晚期肝癌。结果:研究组0.5年生存率为25.00%,1年生存率为18.75%,中位生存时间为7.50个月;对照组0.5年生存率为20.00%,1年生存率为0,中位生存时间为4.05个月。两组生存曲线比较,结果有统计学差异(P<0.01)。根据QOL-LC V2.0量表评定生活质量,研究组在躯体功能、症状、副作用及总量表等方面评分均较对照组升高(P<0.05),而心理功能、社会功能与对照组比较无明显差异(P>0.05)。在血常规、肝肾功及甲胎蛋白测定等实验室检验中,两组治疗前后组间比较无差异(P>0.05)。以患者生存时间作为因变量,以年龄(>50岁或≤50岁)、肝硬化(失代偿期或代偿期)、乙肝病史(有或无)、甲胎蛋白(≥400μg/ml或<400μg/ml)为预后因素并赋值,经多因素Cox逐步回归分析,P均>0.05。结论:重组人血管内皮抑素联合榄香烯能够提高晚期肝癌患者的生存率和生活质量。To study the effect of recombinant endostatin injection and the blood circulation antineoplas-tic agents（elemene）on patients with advanced liver cancer. Methods：All 36 cases with advanced hepatocellular car-cinoma were randomly divided into treatment group contain 16 and control group 20 patients. The treatment group was treated by the human endostatin and elemene. The control group by cinobufacini injection. Results：Survival rate of six months in treatment group was 25. 00% ,rate for a year was 18. 75% ,median survival time for seven months was fif-teen days. In control group 20. 00% survival rate for six months,0 survival rate for a year and the median survival time for four months was five days. Compared the survival curves of these two groups,the results have statistically difference（P ﹤ 0. 01）. According to the QOL in - LC V2. 0 to assess the quality of life,the treatment group＇s physical function,pymptom,side effect and score of total scale were higher than the control group（P ﹤ 0. 05）,and compared with the control group,no significant difference（P ﹥ 0. 05）in the aspects of mental function and social function. In the function of blood,liver and kidney,and alpha - fetoprotein measurement and other laboratory tests,both treatment group and control group had no difference before and after treatment（P ﹥ 0. 05）. Use the survival time as the depend-ent variable,age（ ﹥ 50 years and ≤50 years）,cirrhosis（decompensated and compensated）,hepatitis B history（and without）,AFP（≥400μg/ ml,﹤ 400μg/ ml）as prognostic factors and signment. After multivariate Cox regression a-nalysis,all P ﹥ 0. 05. These independent prognostic factors can not affect the survival time of patients with advanced hepatocellular carcinoma. Conclusion：Human endostatin and elemene can improve the survival rate and quality of life of patients with advanced hepatocellular carcinoma.

关 键 词：重组人血管内皮抑素 榄香烯 晚期肝癌 

分 类 号：R735.7[医药卫生—肿瘤]